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Cyclodextrin- and Calixarene-based Polycationic 
Amphiphiles as Gene Delivery Systems: A Structure-
Activity Relationship Study† 
Laura Gallego-Yerga,a Michela Lomazzi,b Valentina Franceschi,c Francesco Sansone,*b 
Carmen Ortiz Mellet,*a Gaetano Donofrio,*c Alessandro Casnatib and José M. García 
Fernández*d 
Multi-head/multi-tail facial amphiphiles built on cyclodextrin (CD) and calixarene (CA) scaffolds are 
paradigmatic examples of monodisperse gene delivery systems. The possibility to precisely control the 
architectural features at the molecular level offers unprecedented opportunities for conducting 
structure-activity relationship studies. A major requirement for those channels is the design of a 
sufficiently diverse ensemble of compounds for parallel evaluation of their capabilities to condense 
DNA into transfections nanoparticles where the gene material is protected from the environment. Here 
we have undertaken the preparation of an oriented library of -cyclodextrin (CD) and calix[4]arene 
(CA4) vectors with facial amphiphilic character designed to ascertain the effect of the cationic head 
nature (aminothiourea-, arginine- or guanidine-type groups) and the macrocyclic platform on the 
abilities to complex plasmid DNA (pDNA) and in the efficiency of the resulting nanocomplexes to 
transfect cells in vitro. The hydrophobic domain, formed by hexanoyl or hexyl chains, remains constant 
in each series, matching the overall structure found to be optimal in previous studies. DLS, TEM and 
AFM data support that all the compounds self-assemble in the presence of pDNA through a process 
that involves initially electrostatic interactions followed by formation of CD or CA4 bilayers between 
the oligonucleotide filaments. Spherical transfectious nanoparticles that are monomolecular in DNA 
are thus obtained. Evaluation in epithelial COS-7 and human Rhabdomyosarcoma RD-4 cells evidenced 
the importance of having primary amino groups in the vector to warrant high levels of transfection, 
probably because of their buffering capacity. The results indicate that the optimal cationic head 
depends on the macrocyclic core, aminothiourea groups been preferred in the CD series and arginine 
groups in the CA4 series. Whereas the transfection efficiency relationships remain essentially 
unchanged within each series, irrespective of the cell type, the optimal platform (CD or CA4) strongly 
depends on the cell type. The results illustrate the potential of monodisperse vector prototypes and 
diversity-oriented strategies on identifying the optimal candidates for gene therapy applications. 
Introduction 
Gene therapy represents a potent tool for the therapeutic 
treatment of a broad range of genetic and acquired diseases. 
After some controversial failures, the last years have witnessed 
the first really successful applications of this technique, 
opening the possibility to fight pathologies like severe 
immunodeficiencies, the Wiskott-Aldrich syndrome, beta-
thalassaemia, haemophilia, adrenoleukodystrophy and several 
types of cancer,1 with an ever increasing number of clinical 
trials under way.2 In most cases, the delivery of genetic material 
aimed at the correction of defects in the patients cell genome is 
performed by using viruses as vectors in the context of an “ex-
vivo” strategy. Adenoviruses and retroviruses are properly 
modified to eliminate their infectiousness and to incorporate the 
therapeutic sequences. Their efficiency in transfecting cells, 
due to their own nature, does the rest. Yet, the use of viral 
vectors is still accompanied by some not negligible risks, such 
as violent adverse immune responses and genotoxicity,3 and 
limits like complicate and expensive preparation processes, 
production in rather scarce quantities, restricted dimensions of 
the nucleic acid filaments that can be transported or possible 
compromised bioavailability because of their large molecular 
size. These not yet resolved problems fuelled the research of 
alternatives that materialized, in the years, in the development 
of non viral gene vectors based initially on cationic lipids and 
then on cationic polymers, dendrimers and nanoparticles.4 
Among them, some have shown relevant efficiency and 
relatively low toxicity and are widely used in transfection 
protocols. Nevertheless, although some outstanding examples 
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are on record,5 the systems proposed so far cannot really 
replace viruses. For these reasons, it is still today lively the 
effort in the development of new molecules and formulations 
able to deliver nucleic acids into cells with increasing 
efficiency and safety. 
 A main difficulty in non viral gene carrier optimization 
strategies is the multicomponent or polydisperse nature and 
random conformational properties of most of the systems 
currently available, which handicaps establishing reliable 
relationships between chemical structure and transfection 
efficiency. The design of monodisperse, molecularly well-
defined gene vector prototypes, while more challenging, offers 
unprecedented opportunities at this respect. In recent years, 
cyclodextrins (CDs) and calixarenes (CAs) have been proposed 
as central frameworks allowing the controlled incorporation of 
nucleic acid complexation elements.6 While some positive 
results using polycationic hydrophilic derivatives have been 
reported,7 we and others have shown that endowing the vector 
architecture with facial amphiphilicity,8 by installing segregated 
clusters of cationizable and hydrophobic groups at opposite 
rims in the macrocyclic cores, significantly improves the 
nucleic acid condensation abilities and the transfection 
efficiency of the resulting supramolecular nanocomplexes 
(Figure 1).9-12 
 Structure-activity relationship studies independently 
conducted in both series of compounds let identify some 
favourable structural features. Thus, -cyclodextrin (CD)-
based architectures were generally superior to CD or CD 
derivatives13 and dispositions having the cationic heads at the 
primary face and the lipophilic tails at the secondary hydroxyls 
(skirt-type arrangement)14 performed better than analogues 
exhibiting the reversal orientation.15 In the polycationic 
amphiphilic CA family, the reports point to the supremacy of 
the calix[4]arene (CA4) core in the cone conformation with the 
protonable groups at the upper rim.16 The combination of 
thiourea and amine groups at the cationic domain was found 
optimal for CD derivatives,17 whereas arginine clustering 
imparted the highest DNA delivery efficiency in the CA4 
series.16 Copper(I)-catalyzed azide-alkyne cycloaddition 
(CuAAC) and amine-isothiocyanate coupling were 
implemented for “click” multiconjugation, both ligation 
chemistries warranting full homogeneity. Interestingly, in both 
types of macrocycles incorporation of linear six-carbon chains 
at the hydrophobic domain provided the best results. The 
tetradecacationic CD derivative 1a, displaying a dendritic 
presentation of primary amino groups and fourteen hexanoyl 
chains at the secondary hydroxyls, and the tetraarginine-CA4 
conjugate 2d, bearing four hexyl ether substituents, were 
identified as lead compounds within each category (Figure 2).  
 In our ongoing efforts to develop CD and CA-based 
artificial viruses for drug and gene delivery,16 evaluating the 
properties of structurally related series of CD and CA vectors in 
the same cell systems was highly sought. By combining our 
expertise on the chemistry and supramolecular properties of 
both archetypes we are in the position to underpin whether or 
not the macrocyclic platform determines the optimal 






























































































































Herein we report the synthesis of a collection of polycationic 
amphiphilic CD (1a-f) and CA4 (2a-f) homogeneously 
functionalized with the same polar heads at the narrower and 
upper rim, respectively, and distinguished by the cationic 
species introduced: ammonium, arginine and guanidinium 
groups (sub-libraries I-III, Figure 3). The lipophilic domains, 
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on the contrary, were maintained unvaried within a series, 
namely hexanoyl ester groups for the CD derivatives and 
hexyl ether chains for the CA4 counterparts. The relative 
orientation of the multi-head and multi-tail domains remains 
thus constant within each family. A parallel evaluation of the 
ability of these regioselectively functionalized macrocycles to 
condense pDNA into discrete cationic nanoparticles and of their 
in vitro transfection capabilities toward the COS-7 African 
green monkey kidney epithelial and RD-4 human 
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The known polycationic amphiphilic CD derivatives 1a-c, 
bearing aminothiourea head groups, have been previously 
shown to exhibit promising transfection capabilities both in 
vitro13b and, in the case of 1a, also in vivo.14d,f For this reason, 
they were selected as the CD representatives in sub-library I 
for the purpose of this study. The synthesis of the new 
analogues 2a-c, incorporating the same cationic heads in the 
CA4 series, started from the known 5,11,17,23-tetraamino-
25,26,27,28-tetrakis(n-hexyloxy)calix[4]arene 3,10b which was 
transformed into the pivotal tetraisothiocyanate 4 using an 
excess of the  isothiocyanation reagent carbon 
disulfide/bis(tert-butyl) carbonate.18 Reaction of 4 with bis(2-
tert-butyloxycarbonylaminoethyl) amine (5), bis(2-tert-
butyloxycarbonylaminoethyl) 2-aminoethyl amine (6) and 2-
tert-butyloxycarbonylaminoethyl amine (7), in the presence 
of triethylamine, and removal of the carbamate protecting 
group in the thiourea adducts by trifluoroacetic acid (TFA)-
promoted hydrolysis in the presence of triethylsilane (TES) 
afforded the target CA4 facial amphiphiles 2a-c in high yield. 
The final compounds were isolated as the corresponding octa- 
(2a and 2b) or tetra-hydrochloride salts (2c) after repeated 






















3, R = NH2
4, R = NCS
a
5, X = Boc
2a, X = H · HCl
e 6, X = Boc
2b, X = H · HCl
e
7, X = Boc








%;  b)  NH(CH2CH2NHBoc)2,  Et3N,  DCM,  rt,  12  h,  quantitative;  c) 
H2NCH2CH2N(CH2CH2NHBoc)2,  Et3N,  DCM,  rt,  12  h,  99%.  d)  NH2CH2CH2NHBoc, 
Et3N, DCM, rt, 1.2 h, 99%; e) i, TFA/TES/DCM, 5 min, rt; ii, HCl, 99%. 
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 The lead calixarene derivative 2d was the reference 
compound that inspired sub-library II. The homologous-CD 
representative 1d was obtained by hepta-amidation of the per-
(C-6)-cysteaminyl-per-(O-2,O-3)-hexanoyl CD precursor 8, 
accessible in only three steps from CD,13d,19 with the 
commercial protected arginine derivative 9 (10) and final 























10, R1 = Boc; R2 = Pbf











and  conditions:  a) HBTU, DIPEA, DCM,  rt,  12 h,  68%  ; b)  i,  95:2.5:2.5  TFA‐TIS‐




The presence of the cysteaminyl connector releases the steric 
constrain at the primary CD rim and warrants homogeneous 
multiconjugation even for hyperbranched architectures.20 Sub-
library II has been further enriched by synthesizing the 
corresponding 1,2,3-triazol-linked isosters 1e and 2e. Whereas 
the resulting triazole segment is considered to be isosteric of the 
amide functionality, it imparts a higher rigidity thereby 
influencing the conformational properties. Moreover, the 
triazole moiety might actively participate in DNA complexation 
and release by behaving as hydrogen bonding acceptor, and/or 
intercalating DNA, thereby affecting transfection efficiency.21 
The key “click” multiconjugation step involved the copper(I)-
catalyzed azide-alkyne cycloaddition reaction (CuAAC)22 of 
the known hexanoylated heptaazide CD 1213b or the hexyloxy 
tetraazide CA4 derivative 18 with the propargyl-armed arginine 
derivative 11 (13 and 19, respectively). Alkyne 11 was 
prepared by standard amide coupling of the commercial 
protected amino acid 9 with propargylamine, whereas 
installation of the azidomethyl substituents onto the upper rim 
of the CA4 scaffold, to access tetraazide 18, was accomplished 
in four-steps from the tetrahexyl ether precursor 1423 through a 
reaction sequence involving formylation (15), reduction 
(16), replacement of the resulting primary hydroxyl groups 
into chloro groups (17) and nucleophilic displacement of the 
latter by azide anion. Acid-promoted removal of the carbamate 
and sulfonyl protecting groups in the triazole adducts 13 and 19 
afforded the target polycationic amphiphilic clicked clusters 1e 








13, R1 = Boc; R2 = Pbf











14, R = H
15, R = CHO
16, R = CH2OH
17, R = CH2Cl































19, R1 = Boc; R2 = Pbf












In order to evaluate possible synergies between the amino and 
the guanidino groups of polyarginine facial amphiphiles in 
DNA complexation and delivery, the inclusion in our study of 
the polyguanidine analogues 1f and 2f, grouped in sub-library 
III, as controls lacking any amine functionality was considered 
appropriate. Their synthesis was effected by guanidinylation of 
the CD heptaamine 8 and the CA4 tetraamine derivative 20, 
obtained by reduction of tetraazide 18 (see Experimental), 
respectively, with bis-Boc-triflyl guanidine and final hydrolysis 





22, R1 = R2 = Boc




























21, R1 = R2 = Boc









pDNA complexation abilities and nanocomplex 
characterization  
The ability of the CD- and CA4-based polycationic 
amphiphiles 1a-f and 2a-f to complex and protect DNA was 
first examined by electrophoresis mobility shift assays (EMSA) 
and by determining their capability to prevent intercalation of 
GelRedTM (Biotium) used to stain the DNA filaments. The 
luciferase-encoding plasmid DNA (pDNA) pTG11236 (pCMV-
SV40-luciferase-SV40pA, 5739 base pairs) was employed in 
this experimental setting at protonable nitrogen/phosphorous 
(N/P) ratios 1, 2, 5, 10 and 20. The data (Figure 4) evidenced 
that all the tested derivatives were able to fully complex and 
protect pDNA at N/P >2 as indicated by the absence of free 
mobile plasmid in the corresponding lanes. As a general trend, 
sub-library I compounds displaying a dendritic presentation of 
primary amino groups 1a,b or 2a,b were more efficient at 
condensing pDNA than the linear aminothioureido derivatives 
1c or 2c. In sub-library II, amide connectors (1d or 2d) 
performed better than triazol linkers (1e or 2e). Overall, CD-
scaffolded polycations achieved full neutralization of pDNA 
and fully blocked GelRedTM intercalation al lower N/P ratios as 
compared with the respective CA4 counterparts. 
Nanocondensates formulated with 1a-f or 2a-f with the 
pTG11236 plasmid at N/P 5 and 10, for which EMSA indicated 
full pDNA complexation and protection, were characterized by 
dynamic light scattering (DLS) to determine average 
hydrodynamic size and by mixed-mode measurement-phase 
analysis light scattering (M3-PALS) to measure the ζ-potential 
(Figure 5). Apart the two guanidino macrocycles 1f and 2f at 
N/P = 5 that formed aggregates of 160 and 175 nm, 
respectively, all the other compounds gave rise to 
supramolecular species of similar size in the range of 80-120 
nm hydrodynamic diameter with a rather low polydispersity. 
The observed size decrease on going from N/P = 5 to N/P = 10 
for most of the nanoparticles, in spite of the equivalent results 
obtained in EMSA, is indicative of different compaction states. 
Accordingly, the -potential, positive for both N/P values, was 
higher at N/P = 10 (Figure 5 and Tables S1 and S2 in the 
Supplementary material). No significant changes in size or -
potential were observed at higher N/P ratios (data not shown). 
 
Figure  4.  Electrophoresis  mobility  shift  assays  (EMSA)  for  pDNA  complexes 
formulated  with  1a‐f  and  2a‐f  at  different  N/P  ratios  (1,  2,  5,  10  and  20). 
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Figure  5.  Hydrodynamic  diameter  (bars,  nm)  and  potential  (lines,  mV)  of 
complexes  pDNA–polycationic  amphiphilic  derivatives  determined  by  DLS  and 
M3‐PALs analysis. 
Transmission electron microscopy (TEM) of the 
nanocomplexes formulated at N/P 10 confirmed their relatively 
small size and low polydispersity (Figure 6). As previously 
observed for amphiphilic CD aminothiourea polycations,13,14ba 
snake-like ultra-thin structure revealing an alternated 
arrangement of high (dark) and low (light) electron density 
regions was apparent, independently of the sub-library or the 
macrocyclic scaffold. The dark regions account for the DNA 
chain, whereas the lighter regions probably correspond to 





Figure  6.  Schematic  representation  of  the  proposed  mechanism  for  pDNA 
complexation by polycationic amphiphilic macrocycles  (the general cartoon  for 
CA4  derivatives  in  Figure  1  has  been  used)  involving  electrostatically‐driven 
templating  (A) and bilayer  zipping/nanocondensation  (B). The TEM micrograph 
corresponding to the nanocomplexes  formulated with compound 1d at N/P 10,  
is  also  presented  (C).  The  typical  snake‐like  ultra‐thin  structure  can  be 
appreciated in the insert. 
This scenario strongly suggests a compaction mechanism 
involving the polynucleotide chain acting as a template for the 
alignment of the cationic clusters, a process driven initially by 
electrostatic interactions. Zipping of the bilayers with 
simultaneous expelling of hydration water must then take place 
through hydrophobic contacts implying the hydrophobic 
domains, leading to the final nanocondensates (Figure 6). 
Atomic force microscopy (AFM) further confirmed the size, 
spherical shape and monomolecular DNA character of the 
nanocomplexes formulated with 1a-f or 2a-f, irrespective of the 
nature of the protonable groups or the scaffold. Most 
interestingly, this technique allowed monitoring DNA 
compaction by increasing concentrations of the vector. The 
green fluorescence protein (GFP)-encoding plasmid pEGFP-C1 
(4731 bps) was used for that purpose. As a representative 
example, Figure 7 shows the images obtained for sub-library III 
polyguanidine derivatives 1f and 2f. At N/P 0.5 complexation is 
incomplete and free pDNA filaments of about 0.5 m in length 
can be observed together with partially shrunk plasmids. At N/P 
5 all DNA molecules appear as individual nanocondensates. 
 




 In vitro transfection of COS-7 cells 
The CD and CA4:pDNA nanocomplexes (CDplexes and 
calixplexes) obtained by formulation of 1a-f or 2a-f and the 
luciferase-encoding plasmid pTG11236 at N/P 5 and 10, were 
first tested in gene delivery assays towards the COS-7 cell line. 
For comparative purposes, naked pDNA and polyplexes 
formulated with commercial branched polyethyleneimine 
(bPEI) were used as negative and positive controls, 
respectively. The suitability of the vectors for potential 
systemic applications was assessed by additionally performing 
experiments in the presence of 10% serum. The total amount of 
luciferase expressed was normalized to the total amount of 
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proteins produced by untreated cells. Transfection efficiencies 
are thus presented as logarithm of picograms of luciferase 
respect to milligrams of total proteins (Figure 8). 
 
Figure  8.  In  vitro  transfection  efficiency  in  COS‐7  cells  for  CDplexes  and 
calixplexes  formulated with 1a‐f and 2a‐f and pTG11236 plasmid at N/P 5 and 
10,  in  the  absence  or  in  the  presence  of  serum  (10%).  Polyplexes  formulated 
with brached PEI (bPEI) and naked pDNA in the absence (light blue) and presence 
(dark  blue)  of  10%  serum  were  included  as  positive  and  negative  controls, 
respectively. 
Barring the guanidine CA4 cluster 2f, all the CD:pDNA and 
CA4:pDNA formulations showed transfection efficiencies that 
compare favourably with the results obtained for bPEI 
polyplexes and all, without exception, exhibited more favorable 
cell viabilities (Figure 9). Within sub-library I and III 
derivatives, CD-scaffolded vectors 1a-c and 1f proved 
superior to the homologous CA4 partners 2a-c and 2f, but 
excepting for the later pair, differences remained within one 
order of magnitude. In the group of vectors displaying arginine 
groups (sub-library II) the influence of the scaffold is less 
evident. On the other hand, in the CA4 series the presence of 
amide connectors (compound 2d) was somehow more 
favourable as compared to triazol linkers (compound 2e). 
Indeed, compounds 1d, 1e and 2d were as efficient as the lead 
aminothiourea representative 1a and similarly preserved the 
transfection capabilities in serum-containing medium. The most 
striking observation is the dramatic dropping in transfection 
efficiency on comparing sub-libraries II and III. The 
compounds bearing the simple guanidinium units showed by far 
the lowest transfection efficacy among all the synthesized 
compounds. This result suggests that the presence in the vectors 
of nitrogen atoms with the ability to reversibly shift from 
protonated to neutral state in a physiological pH window is 
advantageous, probably by imparting buffering capabilities to 
the corresponding nanoparticles, thereby facilitating endosome 
escape through the so-called proton sponge mechanism.24 
 
Figure 9. Cell viability of COS‐7 cells in the presence of CDplexes and calixplexes 
formulated with 1a‐f  and 2a‐f  and pTG11236 plasmid  at N/P 5  and 10,  in  the 
absence or in the presence of serum (10%). Data for polyplexes formulated with 
brached PEI  (bPEI)  and naked   pDNA  in  the  absence  (light blue)  and presence 
(dark blue) of 10% serum are also included. 
Transfection efficiency towards COS-7 cells was also 
determined using the GFP-encoding plasmid pEGFP-C1 and 
directly monitoring by fluorescence microscopy the expression 
of the GFP protein into the cells as consequence of successful 
transfection. Rather than the amount of protein produced, this 
experiment aims at evaluating the proportion of cells that is 
effectively transfected by each polycationic cluster:pDNA 
formulation. Transfection efficiency is then reported as 
percentage of transfected cells (Figure 11). Given that 
cytoxicity has a strong impact in this assay, for each vector the 
concentration producing the best compromise between cell 
viability and transfection efficiency in the range of 1.25–10 
M, was used. At concentrations lower than those selected the 
cell viability was comparable or higher but the percentage of 
transfected cells lower while at higher concentrations 
cytotoxicity was too high. Cell viabilities, determined by the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) method (see the Supplementary material for 
experimental details) at the concentrations exploited in this 
experimental setting, are collected in Figure 10. In addition to 
PEI-formulated polyplexes, lipoplexes formulated with 
commercial Lipofectamine® (LTX) were included as positive 
controls. Parallel experiments were also performed in the 
presence of dioleoylphosphatidylethanolamine (DOPE), a 
commonly used transfection adjuvant25 that has been previously 
found to improve the transfection efficiency of CA4-scaffolded 
polycationic clusters in some cases.14 Cells treated only with 
DOPE were then used as negative controls. 
Overall, the results obtained using this evaluation protocol 
(Figure 11) qualitatively paralleled those previously obtained 
with the luciferase-encoding plasmid. Thus, the two guanidino 
derivatives 1f and 2f included in sub-library III exhibited the 
poorer transfection abilities among all vectors assayed, with a 
percentage of transfected cells close to zero. In the 
polyaminothiourea series (sub-library I) CD-scaffolded 
derivatives 1a-c proved superior to the corresponding CA4 
analogues 2a-c bearing identical cationic heads, whereas in 
sub-library II amide-linked derivatives 1d and 2d provided 
higher transfection efficiencies as compared with triazol-linked 
analogues 1e and 2e. In any case, only the nanocomplexes 
formulated with the two lead compounds in sublibraries I and 
II, namely the dendritic CD aminothiourea 1a and the amide-
linked CA4 tetraarginine derivative 2d, rivalled lipoplexes 
formulated with LTX. Co-formulation with DOPE was 
detrimental in most cases with the notable exceptions of the 
calixplexes obtained from compounds 2b and 2e, for which a 
quite significant enhancement in the percentage of transfected 
COS-7 cells was observed. 
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Figure 10. Cell  viability  of COS‐7  cells  (MTT determination)  in  the presence of 
nanocomplexes formulated with the pEGFP‐C1 and CD or CA4 polycations 1a‐f 
or 2a‐f at their optimal concentration (M) with and without DOPE (1:2 vector‐




Figure  11.  In  vitro  transfection  efficiency  in  COS‐7  cells  in  the  presence  of 
nanocomplexes formulated with the pEGFP‐C1 and CD or CA4 polycations 1a‐f 
or 2a‐f at their optimal concentration (M) with and without DOPE (1:2 vector‐
DOPE molar  ratio).  Data  for  lipoplexes  formulated with  Lipofectamine®  (LTX), 
and polyplexes  formulated with polyethyleneimine  (PEI) are also shown. C.T.A.: 
Commercial Transfection Agent. 
In vitro transfection of the human Rhabdomyosarcoma RD-
4 cell line 
 
 Human Rhabdomyosarcoma RD-4 cells are a kind of cancer 
cells of connective tissues. The difficulties of the treatment and 
the impossibility, in many cases, of removing the tumor make 
this cell line of high medical relevance for gene therapy. 
Moreover, it is a cell line particularly difficult to transfect. The 
protocol based on the use of the pEGFP-C1 and fluorescence 
microscopy monitoring of the percentage of cells expressing 
GFP after treatment with the nanocomplexes formulated with 
the optimal concentration of each molecular vector, eventually 
co-formulated with DOPE, was applied. This choice keep 
consistency with previous studies on the ability of calixplexes 
to mediate transfection in this particular cell line.12 The 
corresponding cell viability and transfection data are collected 
in Figures 12 and 13, respectively. Formulations prepared with 
LTX and PEI were used as positive controls whereas parallel 
experiments with DOPE alone were conducted as a negative 
control. 
 
Figure  12.  Cell  viability  of  RD‐4  cells  (MTT  determination)  in  the  presence  of 
nanocomplexes formulated with the pEGFP‐C1 and CD or CA4 polycations 1a‐f 
or 2a‐f at their optimal concentration (M) with and without DOPE (1:2 vector‐




Figure  13.  In  vitro  transfection  efficiency  in  RD‐4  cells  in  the  presence  of 
nanocomplexes formulated with the pEGFP‐C1 and CD or CA4 polycations 1a‐f 
or 2a‐f at their optimal concentration (M) with and without DOPE (1:2 vector‐
DOPE molar  ratio).  Data  for  lipoplexes  formulated with  Lipofectamine®  (LTX), 
and polyplexes  formulated with polyethyleneimine  (PEI) are also shown. C.T.A.: 
Commercial Transfection Agent. 
Most of the nanocomplexes formulated with the CD or CA4 
polycationic amphiphiles 1a-f or 2a-f led to GFP expression in 
the RD-4 cell line, but only the lead compound in each series, 
namely the dendritic aminothiourea CD derivative 1a and the 
arginine CA4 derivative 2d, performed better than the 
references LTX and PEI. Both 1a and 2d showed their best 
efficiency when formulated without adjuvant. Actually, as 
already observed in COS-7 cells, the incorporation of DOPE 
was generally detrimental for the activity of the tested ligands. 
The data confirms the high transfection efficiency of the 
argininocalixarene 2d in RD-4 cells. While in the experiments 
with COS-7 cells differences in transfection efficiencies 
between vectors in the tested library remained modest, in the 
case of RD-4 cells the transfection efficiency of the 
argininocalixarene 2d stands out of the rest, with an exceptional 
75% of cells successfully transfected. The dendritic 
aminothiourea CD derivative 1a, which was the best 
performing system in the COS-7 cell line, achieved 50% of 
RD-4 cells transfected, meaning that the optimal vector 
depends on the target cell. In any case, with few exceptions, 
such as the significant transfection level observed for the 
tetraguanidine CA4 derivative 2f in this assay, the data within a 
series follow the same trends already observed in COS-7 cells, 
but differences are quantitatively more pronounced. Thus, the 
proportion of transfected cells drops from 50% or 25% to 
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almost zero on going from the dendritic tetradecacationic 
derivatives 1a or octacationic 2a to the linear heptacationic 1c 
or tetracationic 2c analogues. A high cationic density seems 
thus to be critical for successful transfection of RD-4 cells. 
 
Figure  14.  Optical  (left  columns)  and  fluorescent  (right  columns) microscopy 
images of human RD‐4 cells transfected (in green) upon treatment with EGFP‐C1 
pDNA  (1  nM)  formulated  with  polyaminothiourea  CD  derivative  1a  and 
polyarginine CA4 derivative 2d. 
When comparing homologous CD and CA derivatives in 
each sub-library, barring the 1a/2a pair the calixarene 
derivatives were generally superior to the cyclodextrins vectors, 
which is the opposite situation to that encountered in COS-7 
cells. It has been previously advanced that CD facial 
amphiphiles can interact with cholesterol in the cell membrane 
through inclusion complex formation and that this interaction 
facilitates caveolin-mediated endocytosis (CME) of the 
corresponding CDplexes.9,14a Indeed, CME has been shown to 
be by far the most productive internalization route for 
CDplexes.14a Since caveolin is down-regulated in 
Rhabdomyosarcoma,26 it can be expected that the efficiency of 
CD-based vector will be decreased in RD-4 as compared with 
COS-7 cells. It is interesting to speculate that calixplexes can 
enter the cell through alternative caveolin-independent routes 
that remain productive regarding transfection, which may be at 
the origin of the outstanding result obtained with compound 2d. 
Exploring this hypothesis is currently sought in our 
laboratories. 
Conclusions 
In summary, we have demonstrated that the approach based in 
the installation of counter-directional multi-head/multi-tail 
cationizable/O-hexanoyl or O-hexyl domains onto a -
cyclodextrin or a calix[4]arene platform provides facial 
amphiphiles with gene delivery capability. Total control of the 
homogeneity at the molecular level is warranted in homologous 
series of compounds, allowing reliable structure–activity 
relationship studies. The components of the three sub-libraries 
considered in this study, namely compounds featuring 
aminothiourea, arginine and guanidine clusters were all able to 
condense pDNA into self-assembled nanocomplexes through a 
process that involves electrostatic vector-DNA interactions and 
hydrophobic vector-vector interactions, resulting in a well-
ordered arrangement of alternated DNA chains and vector 
bilayers. As a general trend, increasing the density of 
protonable groups had a beneficial impact in transfection 
capabilities provided that amino groups, with buffering 
capabilities, were present in the structure. The effect of the 
macrocyclic core on his side was more evident when comparing 
different cell lines. In epithelial COS-7 cells from apes, CD 
formulated CDplexes exhibited a higher transfection efficiency 
than the homologous CA4-formulated calixplexes, while the 
reverse situation was encountered in human RD-4 cells. This 
switch can be tentatively ascribed to the operation of different 
cell uptake mechanisms that affect in a dissimilar manner the 
fate of CDplexes and calixplexes. In any case, this work 
provides clues for the rational design of new molecular gene 
delivery systems and validates the strategy based on systematic 
structural modifications in CD and CA-based facial 
amphiphiles and structure-activity relationship studies for the 




Bis(2-tert-butyloxycarbonylaminoethyl) amine and bis(2-tert-
butyloxycarbonylaminoethyl) 2-aminoethyl amine were 
obtained according to literature procedures.13b Optical rotations 
were measured at 20 ± 2 ºC in 1-dm tubes on a Jasco P-2000 
polarimeter. 1H (and 13C NMR) spectra were recorded at 500 
(125.7) MHz with Bruker 500 DRX magnet. 1D TOCSY, 2D 
COSY, HMQC and HSQC experiments were used to assist on 
NMR assignments. Thin-layer chromatography (TLC) was 
carried out on aluminum sheets coated with silica gel 60 F254 
Merck with visualization by UV light and by charring with 
ethanolic 10% H2SO4 or 0.1% ninhydrin. Column 
chromatography was carried out on Silica Gel 60. ESI mass 
spectra were recorded on a Bruker Daltonics Esquire6000™ 
ion-trap mass spectrometer; in some cases, CuI was added as 
cationizing agent. MALDI-TOF mass spectra were registered in 
a Bruker Daltonics Autoflex instrument in the linear positive 
mode with pulse ion extraction; 2,5-dihydroxybenzoic acid 
(DHB) was used as desorption matrix. Elemental analyses were 
carried out at the Instituto de Investigaciones Químicas 
(Sevilla, Spain).  
5,11,17,23-Tetraisothiocyanate-25,26,27,28-tetrakis(n-
hexyloxy)calix[4]arene (4). To a solution of 5,11,17,23-
tetraamino-25,26,27,28-tetrakis(n-hexyloxy)calix[4]arene (3, 
150 mg, 0.183 mmol) in absolute EtOH (4 mL), CS2 (440 μL, 
7.3 mmol) and Et3N (102 μL, 0.73 mmol) were added. The 
reaction mixture was stirred for 2 h at rt and then cooled in an 
ice bath. A solution of Boc2O (158 mg, 0.72 mmol) in absolute 
EtOH (1 mL) was added followed by the addition of a catalytic 
amount of DMAP (1.8 mg, 15 μmol). The reaction mixture was 
kept in the ice bath for 20 min. Then it was allowed to reach rt 
and further stirred for 2 h. The solvent was removed under 
reduced pressure and the residue was purified by column 
chromatography (1:3 DCM-cyclohexane). Yield: 181 mg 
(88%); Rf = 0.67 (1:3 DCM-cyclohexane); 1H NMR (400 MHz, 
CDCl3): δ 6.56 (s, 8 H, Ar), 4.35 (d, J = 10.2 Hz, 4 H, 
ArCHaxAr), 3.83 (t, J = 5.7 Hz, 8 H, CH2-1Hex), 3.09 (d, J = 
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10.2 Hz, 4 H, ArCHeqAr), 1.89-1.77 (m, 8 H, CH2-2Hex), 1.41-
1.28 (m, 24 H, CH2-3Hex, CH2-4Hex, CH2-5Hex), 0.97-0.84 (m, 12 
H, CH3-6Hex); 13C NMR (100.6 MHz, CDCl3): δ 155.7, 135.9 
(Ar), 134.3 (NCS), 125.7, 125.6 (Ar), 75.9 (C-1Hex), 32.1 (C-
3Hex), 30.9 (ArCH2Ar), 30.2 (C-2Hex), 25.9 (C-4Hex), 22.9 (C-
5Hex), 14.2 (C-6Hex); ESI-MS: m/z 1011.1 [M + Na]+; Anal. 
calcd. for C56H68N4O4S4: C 67.98, H 6.93, N 5.66, S 12.96. 
Found: C 68.07, H 6.88, N 5.61, S 12.79. 
5,11,17,23-Tetra-[N’,N’-bis-(2-(tert-butoxycarbonylamino)ethyl)-
thioureido]-25,26,27,28-tetrakis(n-hexyloxy)calix[4]arene (5). A 
solution of 4 (84.1 mg, 0.085 mmol) in dry DCM (3 mL) was added 
dropwise to a solution of N’,N’-bis-(2-(tert-
butoxycarbonylamino)ethylamine (124 mg, 0.41 mmol) and Et3N 
(85 μL, 0.62 mmol) in dry DCM (3 mL). The mixture was stirred 
overnight at rt. The solvent was removed under vacuum and the 
residue was purified by column chromatography (100:1 → 99:1 
DCM-MeOH). Yield: 187 mg (99%); Rf = 0.58 (9:1 DCM-MeOH); 
1H NMR (500 MHz, CD3OD): δ 6.96 (bs, 8 H, Ar), 4.48 (d, J = 12.5 
Hz, 4 H, ArCHaxAr), 4.05-3.70 (m, 24 H, CH2-1Hex, CH2NCS), 3.31 
(bs, 16 H, CH2NHBoc), 3.14 (d, J = 12.5 Hz, 4 H, ArCHeqAr), 2.07 
(m, 8 H, CH2-2Hex), 1.67-1.28 (m, 96 H, CMe3, CH2-3Hex, CH2-4Hex, 
CH2-5Hex), 1.05-0.95 (m, 12 H,  CH3-6Hex); 13C NMR (125.7 MHz, 
CD3OD, 333K): δ 183.2 (CS), 158.5 (CO), 155.3-127.3 (Ar), 80.7 
(CMe3), 76.6 (C-1Hex), 52.4 (CH2NHCS), 39.7 (CH2NHBoc), 33.3 
(C-3Hex), 32.0 (ArCH2Ar), 31.5 (C-2Hex), 29.0 (CMe3), 27.2 (C-4Hex), 
23.9 (C-5Hex), 14.4 (C-6Hex); ESI-MS: m/z 2265.9 [M + Cu]+, 1144.9 
[M + Cu + Na]2+; Anal. calcd. for C112H184N16O20S4: C 61.06, H 
8.42, N 10.17, S 5.82. Found: C 61.30, H 8.30, N 9.88, S 5.88. 
5,11,17,23-Tetra-[bis-2-(aminoethyl)thioureido]-25,26,27,28-
tetrakis-(n-hexyloxy)calix[4]arene octahydrochloride (2a). A 
solution of 5 (25 mg, 11 μmol) in DCM-TFA-TES (87.5:10:2.5, 3 
mL) was stirred at 0 °C for 2 h. The solvent was removed under 
reduced pressure. The residue was precipitated and washed with 
Et2O (5 mL). Then the solid was dissolved in an aqueous 0.1 M HCl 
solution and concentrated to give the product as hydrochloride. 
Yield: 19 mg (99%); 1H NMR (300 MHz, CD3OD): δ 6.86 (s, 8 H, 
Ar), 4.50 (d, J = 12.6 Hz, 4 H, ArCHaxAr), 4.09 (t, J = 6.7 Hz, 16 H, 
CH2NHCS), 3.96 (t, J = 7.8 Hz, 8 H, CH2-1Hex), 3.26 (t,  J = 6.7 Hz, 
16 H, CH2NH2), 3.16 (d, J = 12.6 Hz, 4 H, ArCHeqAr), 2.11-1.95 (m, 
8 H, CH2-2Hex), 1.56-1.32 (m, 24 H, CH2-3Hex, CH2-4Hex, CH2-5Hex), 
1.02-0.90 (m, 12 H, CH3-6Hex); 13C NMR (125.7 MHz, CD3OD, 313 
K): δ 184.3 (CS), 155.5-127.9 (Ar), 76.9 (C-1Hex), 48.65 
(CH2NHCS), 38.4 (CH2NH2), 33.4 (C-3Hex), 31.8 (ArCH2Ar), 31.6 
(C-2Hex), 27.1 (C-4Hex), 23.9 (C-5Hex), 14.5 (C-6Hex); ESI-MS: m/z 
1463.9 [M + Cu]+; Anal. calcd. for C72H128Cl8N16O4S4: C 51.06, H 
7.62, N 13.23, S 7.57. Found: C 50.77, H 7.59, N 12.91, S 7.19. 
5,11,17,23-Tetra-[2-N’-(N,N-bis-(2-(tert-
butoxycarbonylamino)ethyl)amino)-ethyl)-thioureido]-
25,26,27,28-tetrakis-(n-hexyloxy)calix[4]arene (6). A solution of 4 
(40 mg, 0.040 mmol) in dry DCM (3 mL) was added dropwise to a 
solution of 2-[bis-[2-(tert-butoxycarbonylamino)-
ethyl]amino]ethylamine (67.4 mg, 0.19 mmol) and Et3N (40 μL, 
0.28 mmol) in dry DCM (3 mL). The mixture was stirred overnight 
at rt. The solvent was removed under vacuum and the residue was 
purified by column chromatography (19:1 DCM-MeOH). Yield: 95 
mg (99%); Rf = 0.56 (9:1 DCM-MeOH); 1H NMR (300 MHz, 
CD3OD): δ 6.721 (bs, 8 H, Ar), 4.47 (d, J = 12.9 Hz, 4 H, 
ArCHaxAr), 3.93 (m, 8 H, CH2-1Hex), 3.69-3.53 (m, 8 H, CH2NHCS), 
3.20 (d, J = 13.3 Hz, 4 H, ArCHeqAr), 3.07 (t, J = 6.4 Hz, 16 H, 
CH2CH2NHBoc), 2.77-2.65 (m, 8 H, CH2CH2NHCS), 2.64-2.53 (m, 
16 H, CH2CH2NHBoc), 2.06-1.89 (m, 8 H, CH2-2Hex), 1.62-1.25 (m, 
96 H, CMe3, CH2-3Hex, CH2-4Hex, CH2-5Hex), 1.02-0.87 (m, 12 H, 
CH3-6Hex); 13C NMR (75 MHz, CD3OD, 313 K): δ 181.7 (CS), 158.4 
(CO), 155.9-126.1 (Ar), 80.3 (CMe3), 76.6 (C-1Hex), 55.3 
(CH2NHBoc), 54.4 (CH2CH2NHCS), 43.8 (CH2NHCS), 40.1 
(CH2CH2NHBoc), 33.3 (C-3Hex), 32.0 (ArCH2Ar), 31.5 (C-2Hex), 
29.0 (CMe3), 27.3 (C-4Hex), 23.9 (C-5Hex), 14.4 (C-6Hex); ESI-MS: 
m/z 2397.3 [M + Na]+, 1209.6 [M + 2Na]2+; Anal. calcd. for 
C120H204N20O20S4: C 60.68, H 8.66, N 11.79, S 5.40. Found: C 
60.52, H 8.58, N 11.62, S 5.24. 
5,11,17,23-Tetra-[2-N’-(N,N-bis-(2-ethylamino)ethyl)thioureido]-
25,26,27,28-tetrakis-(n-hexyloxy)calix[4]arene (2b). A solution of 
6 (52 mg, 22 μmol) in TFA (0.4 mL) was stirred at rt for 5 min. H2O 
(10 mL) was added and the solution was freeze-dried. The residue 
was dissolved in 0.1 M HCl methanolic solution and freeze-dried to 
obtain the product as hydrochloride. Yield: 41 mg (99%); 1H NMR 
(300 MHz, CD3OD): δ 7.02 (bs, 8 H, Ar), 4.51 (d, J = 12.7 Hz, 4 H, 
ArCHaxAr), 4.18 (t, J = 7.2 Hz, 8 H, CH2-1Hex), 3.96 (t, J = 7.7 Hz, 8 
H, CH2NHCS), 3.37-3.26 (m, 40 H, CH2CH2NHBoc, 
CH2CH2NHCS, CH2CH2NHBoc), 3.21 (d, 4 H, ArCHeqAr), 2.18-
2.06 (m, 8 H, CH2-2Hex), 1.56-1.34 (m, 24 H, CH2-3Hex, CH2-4Hex, 
CH2-5Hex), 1.05-0.89 (m, 12 H, CH3-6Hex); 13C NMR (125.7 MHz, 
CD3OD): δ 183.9 (CS), 155.4-127.8 (CAr), 76.5 (C-1Hex), 51.5, 51.8 
(CH2N(CH2CH2)2), 42.2 (CH2NHCS), 37.9 (CH2NH2), 32.5 (C-
3Hex), 31.3 (ArCH2Ar), 30.8 (C-2Hex), 26.7 (C-4Hex), 23.4 (C-5Hex), 
14.4 (C-6Hex); ESI-MS: m/z 1574.9 [M + H]+, 788.0 [M + 2H]2+; 
Anal. calcd. for C80H152Cl12N20O4S4: C 47.76, H 7.62, N 13.92, S 
6.38. Found: C 47.67, H 7.72, N 13.90, S 6.29.  
5,11,17,23-Tetra-[N’-(2-(tert-butoxycarbonylamino)-
ethyl)thioureido]-25,26,27,28-tetrakis-(n-hexyloxy)calix[4]arene 
(7). A solution of 4 (84.1 mg, 0.085 mmol) in dry DCM (3 mL) was 
added dropwise to a solution of commercial N’-(2-tert-
butoxycarbonylamino)ethylamine (67 mg, 0.41 mmol) and Et3N (85 
μL, 0.62 mmol) in dry DCM (3 mL). The mixture was stirred 
overnight at rt, .the solvent was removed under vacuum and the 
residue was purified by column chromatography (95:5 → 9:1 DCM-
MeOH). Yield: 138 mg (99%); Rf = 0.61 (9:1 DCM-MeOH); 1H 
NMR (400 MHz, CD3OD): δ 6.68 (bs, 8 H, Ar), 4.46 (d, J = 12.7 
Hz, 4 H, ArCHaxAr), 3.93 (t, J = 7.9 Hz, 8 H, CH2-1Hex), 3.65 (t, J = 
6.0 Hz, 8 H, CH2NHCS), 3.34-3.16 (m, 12 H, ArCHeqAr, 
CH2NHBoc), 2.06-1.91 (m, 8 H, CH2-2Hex), 1.55-1.32 (m, 60 H, 
CH2-3Hex, CH2-4Hex, CH2-5Hex, CMe3), 1.01-0.92 (m, 12 H, CH3-
6Hex); 13C NMR (100.6 MHz, CD3OD): δ 181.6 (CS), 158.8 (CO), 
155.8-125.9 (Ar), 80.2 (CMe3), 76.7 (C-1Hex), 45.9 (CH2NHCS), 
40.8 (CH2NHBoc), 33.4 (C-3Hex), 31.9 (ArCH2Ar), 31.6 (C-2Hex), 
28.9 (CMe3), 27.3 (C-4Hex), 24.1 (C-5Hex), 14.5 (C-6Hex);  ESI-MS: 
m/z 1651.8 [M + Na]+, 1667.8 [M + K]+; Anal. calcd. for 
C84H132N12O12S4: C 61.88, H 8.16, N 10.31, S 7.87. Found: C 61.85, 
H 8.29, N 10.24, S 7.79. 
5,11,17,23-Tetraaminoethylthioureido-25,26,27,28-tetrakis(n-
hexyloxy)-calix[4]arene (2c). A solution of 7 (40 mg, 25 μmol) in 
DCM-TFA-TES (87.5:10:2.5, 0.5 mL) was stirred at 0 °C for 2 h. 
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The solvent was removed and the residue was precipitated and 
washed with Et2O. Then the solid was dissolved in an aqueous 0.1 M 
HCl solution and concentrated to yield the product as hydrochloride. 
Yield: 33.8 mg (99%); 1H NMR (500 MHz, CD3OD): δ 6.72 (bs, 8 
H, Ar), 4.47 (d, J = 13.2 Hz, 4 H, ArCHaxAr), 3.98-3.85 (m, 16 H, 
CH2-1Hex, CH2NHCS), 3.26-3.13 (m, 12 H, ArCHeqAr, CH2NH2), 
2.02-1.88 (m, 8 H, CH2-2Hex), 1.56-1.35 (m, 24 H, CH2-3Hex, CH2-
4Hex, CH2-5Hex), 0.99-0.91 (m, 12 H, CH3-6Hex); 13C NMR (75 MHz, 
CD3OD): δ 182.8 (CS), 156.0-125.7 (Ar), 76.7 (C-1Hex), 42.8 
(CH2NHCS), 40.8 (CH2NH2), 33.4 (C-3Hex), 31.9 (ArCH2Ar), 31.5 
(C-2Hex), 27.3 (C-4Hex), 24.0 (C-5Hex), 14.5 (C-6Hex); ESI-MS: m/z 
1291.4 [M + Cu]+; Anal. calcd. for C64H100N12O4S4·4HCl: C 55.88, 
H 7.62, N 12.22, S 9.32. Found: C 55.59, H 7.56, N 11.92, S 9.03. 
Heptakis[6-(2-(4-(Nα-tert-butoxycarbonylamino-Nω-(2,2,4,6,7-
pentamethyldihydrobenzofurane-5-sulfonyl)-L-arginine-N-
amide)ethylthio)-2,3-di-O-hexanoyl]cyclomaltoheptaose (10). To 
a solution of heptakis[2,3-di-O-hexanoyl-6-(2-aminoethylthio)]-
cyclomaltoheptaose heptahydrochloride (8, 154, 60 mg, 19 μmol) in 
dry DCM (4 mL), under Ar atmosphere, DIPEA (90 μL, 53 μmol), 
Nα-tert-butoxycarbonylamino-Nω-(2,2,4,6,7-pentamethyldihydro-
benzofurane-5-sulfonyl)-L-arginine (9, Nα-Boc-N-Pbf-L-arginine) 
(104 mg, 198 μmol) and O-(benzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate (HBTU) (75 mg, 198 
μmol) were added and the mixture was stirred overnight. The 
reaction mixture was washed with an aqueous solution of NaHCO3 
(8 mL), the organic layer was dried (MgSO4), filtered and 
concentrated. The residue was purified by column chromatography 
(25:1 → 18:1 DCM-MeOH). Yield: 83 mg (68%); Rf = 0.43 (17:1 
DCM-MeOH). [α]D = +31.9 (c 1 in MeOH); 1H NMR (500 MHz, 
CD3OD): δ 5.54 (t, 7 H, J2,3 = J3,4 = 9.5 Hz, H-3), 5.36 (d, J1,2 = 3.7 
Hz, 7 H, H-1), 5.02 (dd, 7 H, H-2), 4.41 (m, 7 H, H-5), 4.33-4.23 (m, 
7  H, CH-2Arg), 4.12 (m, 7 H, H-4), 3.76-3.67 (m, 7 H, CH2NHCO), 
3.64-3.55 (m, 7 H, CH2NCO), 3.48-3.28 (s, 28 H, CH2-5Arg, H6a, 
H6b), 3.17 (s, 14 H, MePbf), 3.07-2-96 (m, 14 H, CH2S), 2.77 (s, 21 
H, MePbf), 2.71 (s, 21 H, MePbf), 2.57-2.38 (m, 28 H, CH2-2Hex), 2.26 
(s, 21 H, MePbf), 2.03-1.93 (m, 7 H, CH2-3Arg), 1.91-1.71 (m, 49 H, 
CH2-3Arg, CH2-4Arg, CH2-3Hex), 1.63 (bs, 42 H, CMe2 Pbf), 1.61 (bs, 
63 H, CMe3), 1.59-1.44 (m, 56 H, CH2-4Hex, CH2-5Hex), 1.20-1.05 
(m, 42 H, CH3-6Hex);13C NMR (75 MHz, CD3OD): δ 174.9, 174.7 
(CO ester), 173.5 (CO amide), 159.9 (CN), 158.1 (CO carbamate), 
157.7-118.4, (CqPbf ), 98.2 (C-1), 87.7 (CMe3), 80.7 (CMe2Pbf), 71.7 
(C-4), 73.5 (C-5), 71.7, 71.6 (C-2, C-3), 55.8 (CH2-2Arg), 44.1 
(CH2Pbf), 41.5 (CH-5Arg), 40.5 (CH2NHCO), 35.1, 35.0 (C-2Hex, C-6), 
34.1 (CH2S), 32.6, 32.5 (C-4Hex), 30.9 (CH2-3Arg), 28.9, 28.8 
(CMe2Pbf, CMe3), 27.1 (CH2-4Arg), 25.6 (C-3Hex), 23.6 (C-5Hex), 19.8,  
18.6 (MePbf), 14.6 (C-6Hex), 12.7 (MePbf); ESI-MS: m/z 3263.3 [M + 
2 Na]2+, 2182.6 [M + 3 Na]3+; Anal. calcd. for C308H497N35O84S14: C 
57.06, H 7.73, N 7.56, S 6.92. Found: C 56.88, H 7.64, N 7.34, S 
6.63. 
Heptakis[6-(2-(4-L-arginine-N-amide)ethylthio)-2,3-di-O-
hexanoyl]-cyclomaltoheptaose tetradecachlorohydrate (1d). A 
solution of 10 (37.5 mg, 6 μmol) in TFA-TIS-H2O (95:2.5:2.5, 4 
mL) was stirred at rt for 1 h. The solvent was removed under 
reduced pressure and coevaporated several times with H2O. The 
residue was dissolved in an aqueous solution 0.1 M HCl solution and 
freeze-dried to obtain the product as hydrochloride. Yield: 41 mg 
(99%); [α]D = +9.7 (c 1.0 in DMSO); 1H NMR (500 MHz, DMSO-
d6, 323 K): δ 8.96 (bs, 7 H, NHCO), 8.51-8.29 (m, 14 H, NH2Arg), 
7.93-7.77 (bs, 7 H, NH guanidine), 7.44-7.09 (m, 21 H, NH, NH2 
guanidine), 5.25 (t, J2,3 = J3,4 = 9.0 Hz, 7 H, H-3), 5.09 (bs, 7 H, H-
1), 4.69 (bd, 7 H, H-2), 4.17-4.07 (m, 7 H, H-5), 3.99-3.83 (m, 14 H, 
CH2-5Arg, H-4), 3.43-3.32 (bs, 14 H, CH2N), 3.29-3.19 (bs, 7 H, 
CH2-5Arg), 3.15-2.99 (m, 14 H, H-6a, H-6b), 2.87-2.66 (m, 14 H, 
CH2S), 2.44-2.29 (m, 7 H, CH2-2Hex), 2.26-2.11 (m, 7 H, CH2-2Hex), 
1.92-1.80 (m, 14 H, CH2-3Arg), 1.70-1.58 (m, 14 H, CH2-4Arg), 1.58-
1.45 (m, 28 H, CH2-3Hex), 1.35-1.19 (bs, 56 H, CH2-4Hex, CH2-5Hex), 
0.93–0.78 (m, 42 H, CH3-6Hex); 13C NMR (125.7 MHz, DMSO-d6, 
323 K): δ 175.7, 174.5 (CO ester), 177.8 (CO amide), 161.2 (CN), 
99.4 (C-1), 81.3 (C-4), 74.3 (C-5), 73.1 (C-2), 72.9 (C-3), 55.1 
(CH2-2Arg), 43.7 (CH2-5Arg), 42.4 (CH2NHCO), 36.5, 36.3 (C-2Hex, 
C-6), 35.3 (CH2S), 33.9, 33.8 (C-4Hex), 31.4 (CH2-3Arg), 27.2 (CH2-
4Arg), 26.9, 26.8 (C-3Hex), 24.9, 24.8 (C-5Hex), 16.65, 16.63 (C-6Hex); 
MALDI-MS: m/z 4017.86 [M + H]+; Anal. calcd. for 
C182H343Cl14N35O49S7·7 H2O: C 46.98, H 7.73, N 10.54, S 4.82. 
Found: C 47.01, H 7.50, N 10.48, S 4.75. 
Nα-tert-butoxycarbonylamino-Nω-(2,2,4,6,7-pentamethyldihydro-
benzofurane-5-sulfonyl)-L-arginine-N-propargylamide (11). A 
mixture of Nα-Boc-N-Pbf-L-arginine (1g, 1.9 mmol), DIPEA (0.78 
mL, 4.5 mmol) and HBTU (865 mg, 2.28 mmol) were dissolved in 
dry DMF (15 mL), under Ar atmosphere. After stirring for 30 min at 
rt, propargylamine (0.146 mL, 2.28 mmol) was added and the 
mixture was stirred for 15 h. The solvent was removed under 
reduced pressure and the residue was dissolved in EtOAc (15 mL), 
the organic layer was washed with aqueous saturated NaHCO3 (15 
mL), H2O (15 mL), dried (MgSO4), filtered and concentrated. The 
residue was purified by column chromatography (1:2 → 3:1 EtOAc-
cyclohexane). Yield: 935 mg (87%); Rf = 0.41 (19:1 DCM-MeOH); 
[α]D = +0.9 (c 1.0 in MeOH).  1H NMR (500 MHz, CDCl3): δ 7.34 
(bs, 1 H, NHCO), 6.27 (m, 3 H, NH), 5.59 (bs, 1 H, NHBoc), 4.20 
(bs, 1 H, CH-2Arg), 3.99 (m, 2 H, CH2-Alkyne), 3.27 (bs, 2 H, CH2-
5Arg), 2.96 (s, 2 H, CH2 Pbf), 2.51 (s, 3 H, MePbf), 2.50 (s, 3 H, MePbf), 
2.18 (t, J = 2.5 Hz, 1 H, CH-Alkyne), 2.09 (s, 3 H, MePbf), 1.81 (m, 2 
H, CH2-3Arg), 1.60 (m, 2 H, CH2-4Arg), 1.46 (s, 6 H, CMe2 Pbf), 1.41 
(s, 9 H, CMe3); 13C NMR (100.6 MHz, CDCl3): δ 165.9 (CO amide), 
159.0 (CAr), 156.8 (CN), 156.1 (CO carbamate), 138.3-117.6 (CAr), 
86.4 (CMe2), 80.2 (CMe3), 79.6 (Cq alkyne), 71.4 (CH alkyne), 60.4 
(CHNHBoc), 43.2 (CH2 Pbf, CH2-5Arg), 29.9 (CH2-4Arg), 29.1 (CH2-
6Arg), 28.6 (CMe2), 28.3 (CMe2), 19.3, 17.9, 12.5 (Me Pbf); ESI-MS: 
m/z 586.3 [M + Na]+, 602.1 [M + K]+; Anal. calcd. for C27H41N5O6S: 





triazol-1-yl]cyclomaltoheptaose (13). To a solution of heptakis[6-
azido-6-deoxy-2,3-di-O-hexanoyl]cyclomaltoheptaose (12, 88 mg, 
33 μmol) in acetone (5 mL), Nα-tert-12-Nω-(2,2,4,6,7-
pentamethyldihydrobenzofurane-5-sulfonyl)-L-arginine-N-
propargylamide (11, 142 mg, 0.25 mmol), N,N-
diisopropylethylamine (38μL, 0.24 mmol) and CuI·P(OEt)3 (8.0 mg, 
25μmol) were added. The reaction mixture was refluxed for 48 h. 
The solvent was removed under reduced pressure and the residue 
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was purified by column chromatography (20:1 → 9:1 DCM–
MeOH). Yield: quantitative; Rf = 0.60 (9:1 DCM-MeOH); [α]D = 
+29.7 (c 1.0 in MeOH); 1H NMR (500 MHz, DMSO-d6) δ 8.12 (bs, 
7 H, CHtriazole), 7.84 (bs, 7 H, Ar), 6.69 (bs, 7 H, NH2 guanidine), 6.55 
(bs, 14 H, NH2 guanidine), 5.48-5.35 (m, 14 H, H-3, H-1), 4.74-4.59 
(m, 21 H, CH2NHCO amide, H-2), 4.57-4.54 (m, 7 H, H-5), 4.41-
4.36 (m, 7 H, H-6a), 4.23-4.11 (m, 7 H, H-6b), 3.95 (m, 7 H, CHArg), 
3.61 (bt, 7 H, H-4), 3.09 (m, 14 H, CH2-5Arg), 2.96 (s, 14 H, CH2 Pbf), 
2.51 (s, 21 H, CH3 Pbf), 2.46 (s, 21 H, CH3 Pbf), 2.28–2.26 (m, 7 H, 
CH2-2Hex), 2.27–2.10 (m, 7 H, CH2-2Hex), 2.03 (s, 21 H, CH3 Pbf), 
1.66-1.18 (217 H, CH2-2Arg, CH2-4Arg, CH2-3Hex, CH2-4Hex, CH2-5Hex, 
CH3 Pbf, C(CH3)3), 0.93-0.80 (bs, 21 H, CH3-6Hex); 13C NMR (125.7 
MHz, DMSO-d6) δ 175.3, 175.1 (CO ester), 174.3 (CO amide), 160.6 
(CN guanidine), 159.3 (CO carbamate), 147.6 (C-4triazole), 140.3-
134.6, (Cq Pbf), 127.8 (C-5 triazole), 127.3, 119.3 (Cq Pbf), 99.0 (C-1), 
89.2 (CMe3), 81.3 (CMe2 Pbf), 79.6 (C-4), 72.8 (C-3), 72.5 (C-5), 
72.3 (C-2), 57.2 (CH2-2Arg), 52.6 (CH2NHCO), 45.7 (CH2Pbf), 42.4 
(CH-5-Arg), 37.4 (C-6), 36.4, 36.3 (C-2Hex), 33.9, 33.7 (C-4Hex), 
32.0 (CH2-3Arg), 31.3, 31.2 (CMe2Pbf, CMe3), 28.7 (CH2-4Arg), 26.9, 
26.8 (C-3Hex), 24.8, 24.9 (C-5Hex), 21.8,  20.5 (Me Pbf), 16.6 (C-6Hex), 
15.2 (MePbf); ESI-MS: m/z 3336.4 [M + 2Na]2+; Anal. calcd. for 
C315H490N56O84S7: C 57.06, H 7.45, N 11.83,  S 3.39. Found: C 
56.78, H 7.20, N 11.47, S 2.92.  
Heptakis[6-deoxy-2,3-di-O-hexanoyl-6-[4-(L-arginine-N-
amidomethyl)-1H-1,2,3-triazol-1-yl]cyclomaltoheptaose 
tetradecahydrochloride (1e). A solution of 13 (45.2 mg, 7 μmol), 
in TFA-TIS-H2O (95:2.5:2.5, 4.5 mL) was stirred at rt for 2 h.  The 
solvent was removed under reduced pressure and coevaporated 
several times with water. The residue was dissolved in a 0.1 M HCl 
solution and freeze-dried to obtain the product as hydrochloride. 
Yield: 35.7 mg (quantitative); [α]D = +46.5 (c 1.0 in DMF);  1H 
NMR (500 MHz, DMSO-d6) δ 8.99 (bs, 7 H, NHamide), 7.99 (m, 21 
H, CHtriazole, NH2 arginine), 7.18 (bs, 21 H, NH2 guanidine, NH guanidine), 
5.41-5.37 (m, 14 H, H-3, H-1), 4.68-4.63 (m, 21 H, H-2, CH2NHCO 
amide), 4.51 (m, 7 H, H-5), 4.36-4.34 (m, 7 H, H-6a), 4.23-4.21 (m, 
7 H, H-6b), 3.92 (m, 7 H, CHArg), 3.72 (bt, 7 H, H-4), 3.19 (m, 14 H, 
CH2-5Arg), 2.37–1.93 (m, 28 H, CH2-2Hex), 2.27–2.10 (m, 14 H, CH2-
2Hex), 1.86-1.79 (m, 14 H, CH2-2Arg), 1.48-1.38 (m, 42 H, CH2-4Arg, 
CH2-3Hex), 1.37-2.20 (m, 56 H,  CH2-4Hex, CH2-5Hex),  0.94-0.80 (bs, 
21 H, CH3-6Hex); 13C NMR (125.7 MHz, DMSO-d6): δ 172.8, 171.8 
(CO ester), 169.1 (CO amide), 157.7 (CN guanidine), 144.2 (C-
4triazole), 125.7 (C-5triazole), 102.5 (C-1), 77.3 (C-4), 70.3 (C-3), 70.1 
(C-5), 69.7 (C-2), 52.5 (CH-2Arg), 49.9 (CH2NHCO), 40.7 (CH-5-
Arg), 34.9 (C-6), 33.8, 33.7 (C-4Hex), 31.2, 31.1 (C-4Hex), 28.5 (CH2-
3Arg), 24.3, 24.2 (C-3Hex,CH2-4Arg), 22.2, 22.1 (C-5Hex), 13.9 (C-
6Hex); MALDI-MS: m/z 4163.60 [M + H]+; Anal. calcd. for 
C189H329Cl14N56O49: C 48.57, H 7.25, Cl 10.62, N 16.78, O 16.78. 
Found: C 48.33, H 6.82, N 16.49.  
5,11,17,23-Tetraformyl-25,26,27,28-tetrakis(n-
hexyloxy)calix[4]arene (15). A solution of hexamethylenetetramine 
(16.57 g, 118.3 mmol) in TFA (150 mL) was stirred at 100 C for 10 
min. Then, 25,26,27,28-tetrakis(n-hexyloxy)calix[4]arene (14, 2.5 g, 
3.29 mmol) was added and the mixture was stirred at reflux for 2 
days. The reaction was quenched by addition of HCl 1 M (400 mL) 
and stirred for 3h. The aqueous layer was extracted twice with DCM 
(250 mL); the combined organic phases were washed with a 
saturated aqueous solution of NaHCO3 (200 mL) and brine (200 
mL), dried (Na2SO4) and filtered. The solvent was removed under 
reduced pressure. The product was purified by crystallization from 
hexane (50 mL). Yield: 2.75g (96%); Rf = 0.20 (2:3 EtOAc-
cyclohexane);  1H NMR (300 MHz, CDCl3) δ 9.58 (s, 4 H, CHO), 
7.15 (s, 8 H, Ar), 4.49 (d, J = 13.8 Hz, 4 H, ArCHaxAr), 3.96 (t, J = 
7.5 Hz, 8 H, CH2-1Hex), 3.34 (d, J = 13.8 Hz, 4 H, ArCHeqAr), 2.00-
1.80 (m, 8 H, CH2-2Hex), 1.50-1.20 (m, 24 H, CH2-3Hex, CH2-4Hex, 
CH2-5Hex), 1.00-0.80 (m, 12 H, CH3-6Hex); 13C NMR (100.6 MHz, 
CDCl3) δ 191.3 (CHO), 162.0-130.2 (Ar), 75.8 (C-1Hex), 31.9 (C-
3Hex), 30.9 (ArCH2Ar), 30.3 (C-2Hex), 25.8 (C-4Hex), 22.8 (C-5Hex), 
14.0 (C-6Hex); ESI-MS: m/z 895.9 [M + Na]+; Anal. calcd. for 
C56H72O8: C 77.03, H 8.31. Found: C 76.78, H 8.04. 
5,11,17,23-Tetrahydroxymethyl-25,26,27,28-tetrakis(n-
exyloxy)calix[4]arene (16). To a suspension of 15 (910 g, 1.04 
mmol) in  absolute EtOH (50 mL) at 0 ºC, NaBH4 (0.24 g, 6.25 
mmol)  was added. The mixture was stirred at rt for 18 h. Then, HCl 
1 M (20 mL) was added and the solvents were evaporated under 
reduced pressure. EtOAc (50 mL) was added and the organic layer 
was washed with a saturated aqueous solution of NaHCO3 (50 mL) 
and H2O (50 mL), dried over Na2SO4, and concentrated. Yield: 788 
mg (86%); Rf  = 0.16 (19:1 DCM-MeOH); 1H NMR (300 MHz, 
CD3OD) δ 6.66 (s, 8 H, Ar), 4.46 (d, J = 13.2 Hz, 4 H, ArCHaxAr), 
4.24 (s, 8 H, CH2OH), 3.90 (t, J = 7.2 Hz, 8 H, CH2-1Hex), 3.15 (d, J 
= 13.2 Hz, 4 H, ArCHeqAr), 2.00-1.87 (m, 8 H, CH2-2Hex), 1.52-1.34 
(m, 24 H, CH2-3Hex, CH2-4Hex, CH2-5Hex), 0.95 (t, J = 6.6 Hz, 12 H, 
CH3-6Hex);  13C NMR (100 MHz, CD3OD) δ 157.1-128.3 (Ar), 76.0 
(C-1Hex), 65.1 (CH2OH), 33.1 (C-3Hex), 32.1 (ArCH2Ar), 31.5 (C-
2Hex), 27.3 (C-4Hex), 24.0 (C-5Hex), 14.5 (C-6Hex); ESI-MS: m/z 903.8 
[M + Na]+; Anal. calcd. for C56H80O8: C 76.33, H 9.15. Found: C 
76.41, H 9.20. 
5,11,17,23-Tetrachloromethyl-25,26,27,28-tetrakis(n-
hexyloxy)calix[4]arene (17). To a solution of 16 (600 mg, 0.68 
mmol) in dry DCM (10 mL), SOCl2 (0.99 mL, 13.60 mmol) was 
added dropwise and the mixture was stirred at rt for 4 h. Then, the 
solvent was evaporated under reduced pressure. Yield: 622 mg 
(95%); 1H NMR (400 MHz, CDCl3) δ 6.64 (s, 8 H, Ar), 4.40 (d, J = 
13.2 Hz, 4 H, ArCHaxAr), 4.29 (s, 8 H, CH2Cl), 3.88 (t, J = 7.6 Hz, 8 
H, CH2-1Hex), 3.12 (d, J = 13.2 Hz, 4 H, ArCHeqAr), 1.95-1.80 (m, 8 
H, CH2-2Hex), 1.49-1.19 (m, 24 H, CH2-3Hex, CH2-4Hex, CH2-5Hex), 
1.01-0.77 (m, 12 H, CH3-6Hex); 13C NMR (100 MHz, CDCl3) δ 
157.0-128.6 (Ar), 75.4 (C-1Hex), 46.6 (CH2Cl), 32.0 (C-3Hex), 30.9 
(ArCH2Ar), 30.2 (C-2Hex), 25.9 (C-4Hex), 22.8 (C-5Hex), 14.1 (C-
6Hex); ESI-MS: m/z 977.7 [M + Na]+; Anal. calcd. for C56H76Cl4O4: 
C 70.43, H 8.02. Found: C 70.54, H 8.16. 
5,11,17,23-Tetraazidomethyl-25,26,27,28-tetrakis(n-
hexyloxy)calix[4]arene (18). To a solution of 17 (192 mg, 0.20 
mmol) in dry DMF (7 mL), NaN3 (78.5 mg) was added. The mixture 
was stirred, under Ar atmosphere, at rt, overnight. Then, the solvent 
was evaporated and the crude was dissolved in EtOAc (15 mL). The 
organic layer was washed with H2O (15 mL), dried over MgSO4, 
filtrated and concentrated. The residue was purified by column 
chromatography (cyclohexane → 19:1 cyclohexane-EtOAc). Yield: 
186 mg (95%); Rf  = 0.29 (19:1 cyclohexane-EtOAc); 1H NMR (300 
MHz, CDCl3) δ 6.61 (bs, 8 H, Ar), 4.45 (d, J = 13.2 Hz, 4 H, 
ArCH2axAr), 3.95 (s, 8 H, CH2N3), 3.89 (t, J = 7.5 Hz, 8 H, CH2-
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1Hex), 3.16 (d, J = 13.2 Hz, 4 H, ArCH2eqAr), 1.98-1.85 (m, 8 H, 
CH2-2Hex), 1.48-1.30 (m, 24 H, CH2-3Hex, CH2-4Hex), 0.93 (t, J = 6.9 
Hz, 12 H, CH3-6Hex); 13C NMR (75 MHz, CDCl3) δ 162.1 – 128.2 
(Ar), 75.0 (C-1Hex), 53.8 (CH2N3), 31.7 (C-3Hex), 30.4 (ArCH2Ar), 
29.9 (C-2Hex), 25.5 (C-4Hex), 22.4 (C-5Hex), 13.7 (C-6Hex); ESI-MS: 
m/z 1004.1 [M +Na] +, 1020.0 [M + K] +; Anal. calcd. for 
C56H76N12O4: C 68.54, H 7.81, N 17.13, O 6.52. Found: C 68.60, H 




hexyloxy)calix[4]arene (19). To a solution of 11 (35mg, 35.7 μmol) 
in acetone (5 mL), 18 (104.5 mg, 0.185 mmol), DIPEA (25 μL, 
0.143 mmol) and CuI·P(OEt)3 (5.1 mg, 14.3 μmol) were added. The 
reaction mixture was refluxed for 24 h. The solvent was removed 
under reduced pressure and the residue was purified by column 
chromatography (99:1 → 9:1 DCM–MeOH). Yield: 82 mg (71%); 
Rf = 0.65 (9:1 DCM-MeOH); [α]D = +2.69 (c 1.0 in MeOH), 1H 
NMR (500 MHz, CD3OD, 323 K): δ 7.79 (bs, 4 H, CHtriazole), 6.60 
(bs, 8 H, Ar), 5.25 (bs, 8 H, CH2NHCO amide), 4.50-4.36 (m, 12 H, 
CH2Ar, ArCHaxAr), 4.02 (bs, 4 H, CH-2-Arg), 3.86 (t, J = 7.4 Hz, 8 
H, CH2-1Hex), 3.19-3.02 (m, 12 H, ArCHeqAr, CH2-5-Arg), 2.96 (s, 8 
H, CH2 Pbf), 2.55 (s, 12 H, MePbf), 2.50 (s, 12 H, MePbf), 2.05 (s, 12 
H, MePbf), 1.94-1.85 (m, 8 H, CH2-2Hex), 1.79-1.29 (m, 100 H, CH2-
3Hex, CH2-4Hex, CH2-5Hex, CMe3, CMe2Pbf, CH2-3-Arg, CH2-4-Arg), 
0.98-0.88 (m, 12 H, CH3-6Hex), 13C NMR (100.6 MHz, CD3OD): δ 
173.5 (CO amide), 158.4 (CN guanidine), 156.4 (Ar), 156.2 (CO 
carbamate), 145.0 (C-4triazole) 138.0-128.8 (CqPbf, Ar), 127.9, 124.5 
(Ar), 122.6 (C-5triazole), 116.9 (Ar), 86.2 (CMe2 Pbf), 79.1 (CMe3), 
75.1 (C-1Hex), 54.2 (CH-2-Arg), 53.3 (CH2NHCO), 42.4 (MePbf), 
39.8 (CH2-5-Arg), 34.3 (CH2Ar), 31.8 (C-3Hex), 30.1 (ArCH2Ar), 
30.0 (C-2Hex), 29.0 (CH2-3-Arg), 27.2 (CMe2 Pbf, CMe3), 25.8 (C-
4Hex), 25.5 (CH2-4-Arg), 22.5 (C-5Hex), 18.2, 17.0 (MePbf), 13.0 (C-
6Hex), 11.1 (MePbf); ESI-MS: m/z 1640.4 [M + 2 Na]2+; Anal. calcd. 
for C164H240N32O28S4: C 60.87, H 7.48, N 13.85, S 3.96. Found: C 
60.80, H 7.43, N 13.89, S 3.82. 
5,11,17,23-Tetra-(4-(L-arginine-N-amidomethyl)-1H-1,2,3-
triazol-1-methyl)-25,26,27,28-tetrakis(n-hexyloxy)calix[4]arene 
octahydrochloride (2e). A solution of 14 (20 mg, 6.18 μmol) in 
TFA-TIS-H2O (95:2.5:2.5, 2 mL) was stirred at rt for 1 h. The 
solvent was removed under reduced pressure and the residue was 
washed with EtOAc (15 mL). Then the solid was dissolved in 0.1 M 
HCl solution followed by evaporation under reduced pressure to 
obtain the product as hydrochloride. Yield: 13 mg (99%). [α]D = 
+21.4 (c 1.0 in MeOH); 1H NMR (300 MHz, CD3OD): δ 8.21 (bs, 4 
H, CHtriazole), 6.71 (bs, 8 H, Ar), 5.39 (bs, 8 H, CH2NHCO amide), 
4.75-4.50 (m, 8 H, ArCH2), 4.44 (d, J = 13.2 Hz, ArCHaxAr), 4.00 (t, 
J = 7.39 Hz, 4 H, CH-2-Arg), 3.85 (t, J = 7.4 Hz, 8 H, CH2-1Hex), 
3.27-3.08 (m, 12 H, CH2-5-Arg, ArCHeqAr,), 2.08-1.82 (m, 16 H, 
CH2-3-Arg, CH2-4-Arg), 1.78-1.61 (m, 8 H, CH2-2Hex), 1.53-1.33 
(m, 24 H, CH2-3Hex, CH2-4Hex, CH2-5Hex), 1.00-0.90 (m, 12 H, CH3-
6Hex); 13C NMR (75 MHz, CD3OD): δ 170.2 (CO amide), 158.6 (CN 
guanidine), 158.2, 137.0 (Ar), 136.8 (C-4triazole), 130.0, 129.8 (Ar), 
129.7 (C-5triazole), 76.6 (C-1Hex), 55.6 (CH-2-Arg), 54.1 (CH2NHCO), 
41.8 (CH-5-Arg), 35.5 (CH2Ar), 33.3 (C-3Hex), 31.6 (ArCH2Ar), 
31.5 (C-2Hex), 29.6 (CH2-3-Arg), 27.3 (C-4Hex), 25.4 (CH-4-Arg), 
24.0 (C-5Hex), 14.5 (C-6Hex); ESI-MS: m/z 610.0 [M + 3 H]3+, 914.4 
[M + 2 H]2+, 936.3 [M + 2 Na]2+, 952.3 [M + 2 K]2+; Anal. calcd. for 
C92H152Cl8N32O8  4 H2O: C 50.45, H 7.36, N 20.47. Found: C 50.48, 
H 7.34, N 20.51. 
5,11,17,23-Tetraaminomethyl-25,26,27,28-tetrakis(n-
hexyloxy)calix[4]arene tetrahydrochloride (20). To a solution of  
18 (300 mg, 0.306 mmol) in EtOAc-EtOH (1:1, 50 mL), a catalytic 
amount of Pd/C (30 mg) and 1 M HCl (4 mL) were added. 
Hydrogenation was carried out at 2 atm for 48 h. Then, the catalyst 
was filtered and the solvent was removed under reduced pressure. 
Yield: 313 mg (99%); 1H NMR (400 MHz, CD3OD): δ 6.87 (s, 8 H, 
Ar), 4.49 (d, J = 13.2 Hz, 4 H, ArCHaxAr), 3.92 (t, J = 7.2 Hz, 8 H, 
CH2-1Hex), 3.84 (s, 8 H, CH2NH2), 3.31 (m, 4 H, ArCHeqAr) 2.00-
1.85 (m, 8 H, CH2-2Hex), 1.55-1.30 (m, 24 H, CH2-3Hex, CH2-4Hex , 
CH2-5Hex), 1.00-0.85 (m, 12 H, CH3-6Hex); 13C NMR (100.6 MHz, 
CD3OD): δ 157.0-126.7 (Ar), 75.2 (C-1Hex), 42.6 (CH2NH2), 31.9 
(C-3Hex), 30.3 (ArCH2Ar), 30.1 (C-2Hex), 25.8 (C-4Hex), 22.5 (C-
5Hex), 13.1 (C-6Hex); ESI-MS: m/z 877.6 [M + H]+, 899.8 [M +Na]+; 
Anal. calcd. for C56H88Cl4N4O4: C 65.74, H 8.67, N 5.48. Found: C 
66.91, H 8.37, N 5.62. 
Heptakis[6-(2-(di-tert-butoxycarbonylguanidino)ethylthio)-2,3-
di-O-hexanoyl]-cyclomaltoheptaose (21). To a solution of 
heptakis[2,3-di-O-hexanoyl-6-(2-aminoethylthio)]-
cyclomaltoheptaose heptahydrochloride (8, 50 mg, 15 μmol) in dry 
DCM (5mL), under Ar atmosphere, Et3N (61 μL, 440 μmol) and N-
N’-di-tert-butoxycarbonyl-N’’-tryflylguanidine (86 mg, 220 μmol) 
were added. The reaction mixture was stirred overnight. The reaction 
mixture was washed with an aqueous solution of 2 M KHSO4.  The 
organic layer was washed with a saturated aqueous solution of 
NaHCO3, dried (MgSO4), filtered and concentrated. The residue was 
purified by column chromatography (DCM → 1:4 EtOAc-
cyclohexane). Yield: 67 mg (99%); Rf = 0.75 (1:3 EtOAc-
cyclohexane); [α]D = +30.7 (c 1.0 in MeOH); 1H NMR (300 MHz, 
CD3OD, 313 K): δ 5.33 (t, 7 H, J2,3 = J3,4 = 8.6 Hz, H-3), 5.14 (d, J1,2 
= 3.7 Hz, 7 H, H-1), 4.88 (dd, 7 H, H-2), 4.26–4.15 (m, 7 H, H-5), 
3.93 (t, 7 H, H-4), 3.78-3.53 (m, 14 H, H-6a, H-6b), 3.16 (bs, 14 H, 
CH2NH), 2.98–2.85 (m, 14 H, CH2S), 2.51–2.14 (m, 28 H, CH2-
2Hex), 1.74–1.56 (m, 28 H, CH2-3Hex), 1.57-1.43 (bs, 126 H, CMe3), 
1.45–1.24 (m, 56 H, CH2-4Hex, CH2-5Hex), 1.02-0.85 (m, 42 H, CH3-
6Hex); 13C NMR (75 MHz, CD3OD, 313 K): δ 174.5, 173.4 (CO 
ester), 164.6 (CN), 157.3, 154.2 (CO carbamate), 98.6 (C-1), 84.5 
(C-4), 80.4 (CMe3), 73.0 (C-5), 71.9 (C-3), 71.5 (C-2), 41.4 (C-6), 
35.2, 35.0 (C-2Hex, CH2NH), 34.1 (CH2S), 32.6, 32.5 (C-4Hex), 28.9, 
28.6 (CMe3), 25.6 (C-3Hex), 23.6, 23.5 (C-5Hex), 14.5 (C-6Hex); ESI-
MS: m/z 2332.2 [M + 2 Na]2+, 1562.7 [M + 3 Na]3+; Anal. calcd. for 
C217H371N21O70S7: C 56.43, H 8.10, N 6.37, S 4.86. Found: C 56.26, 
H 8.00, N 6.12, S 4.51. 
Heptakis[6-(2-guanidinoethylthio)-2,3-di-O-hexanoyl]-
cyclomaltoheptaose heptahydrochloride (1f). A solution of 16 (60 
mg, 13 μmol) in DCM-TFA (1:1, 2 mL) was stirred at rt for 3 h. The 
solvent was eliminated under reduced pressure and coevaporated 
several times with water. The residue was disolved in a 0.1 M HCl 
solution and freeze-dried to yield the product as hydrochloride. 
Yield: 45 mg (99%); [α]D = + 68.3 (c 1.0 in DMF); 1H NMR (300 
MHz, CD3OD): δ 5.39 (t, 7 H, J2,3 = J3,4 = 9.4 Hz, H-3), 5.18 (d, J1,2 
= 3.51 Hz, 7 H, H-1), 4.86 (m, 7 H, H-2), 4.16-4.07 (m, 7 H, H-5), 
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3.96 (t, 7 H, H-4), 3.48 (t, 14 H, CH2NH), 3.20-3.11 (m, 14 H. H-6a, 
H-6b), 2.97-2.85 (m, 14 H, CH2S), 2.55-2.21 (m, 28 H, CH2-2Hex), 
1.72–1.55  (m, 28 H, CH2-3Hex), 1.41-1.26 (m, 56 H, CH2-4Hex, CH2-
5Hex), 0.99-0.87 (m, 42 H, CH3-6Hex); 13C NMR (125.7 MHz, 
DMSO-d6, 323 K): δ 172.2, 171.2 (CO), 156.8 (CN), 96.1 (C-1), 
78.0 (C-4), 71.2 (C-5), 69.7 (C-3), 69.8 (C-2), 45.5 (C-6), 40.6 
(CH2NH), 33.1, 32.9 (C-2Hex,) 32.1 (CH2S), 30.6, 30.4 (C-4Hex), 
23.6, 23.5 (C-3Hex), 21.5 (C-5Hex), 13.3, 13.2 (C-6Hex); ESI-MS: m/z 
1609.6 [M + 2 H]2+, 1073.0 [M + 3 H]3+, 805.1 [M + 4 H]4+; Anal. 
calcd. for C147H266Cl7N21O42S7·7 H2O: C 49.06, H 7.84, N 8.17, S 
6.24. Found: C 48.91, H 7.78, N 8.03, S 6.15. 
5,11,17,23-Tetra-[N,N’-di-(tert-butoxycarbonyl)]-
guanidinomethyl-25,26,27,28-tetrakis(n-hexyloxy)calix[4]arene 
(22). To a solution of 20 (100 mg, 0.098 mmol) in dry DCM (5 mL), 
Et3N (137 μL, 0.98 mmol) was added. Then, a solution of N-N’-di-
tert-butoxycarbonyl-N’’-tryflylguanidine (192 mg, 0.49 mmol) in 
dry DCM (1 mL) was added. The mixture was stirred at rt, under N2 
atm, 48 h. The reaction mixture was washed with an aqueous 
solution of 2 M KHSO4- The organic layer was washed with a 
saturated aqueous solution of NaHCO3, dried (MgSO4), filtered and 
concentrated. The residue was purified by column cromatography 
(2:1 DCM-cyclohexane →1:5 EtOAc- cyclohexane). Yield: 165 mg 
(91%); Rf  = 0.24 (1:6 EtOAc - cyclohexane); 1H NMR (300 MHz, 
CDCl3): δ 7.74 (bs, 4 H, NH), 7.55 (bs, 4 H, NH), 6.60 (s, 8 H, Ar),  
4.38 (d, J = 12.8 Hz, 4 H, ArCHaxAr), 4.27 (d, J = 4.4 Hz, 8 H, 
CH2NH), 3.84 (t, J = 7.6 Hz, 8 H, CH2-1Hex), 3.10 (d, J = 13.2 Hz, 4 
H, ArCHeqAr), 1.98-1.85 (m, 8 H, CH2-2Hex), 1.52-1.28 (m, 96 H, 
CH2-3Hex, CH2-4Hex , CH2-5Hex, CMe3) 0.90 (t, J = 6.8 Hz, 12 H, 
CH3-6Hex); 13C NMR (75 MHz, CDCl3): δ 163.6 (CN), 156.1 (Ar), 
155.7, 153.1 (CO carbamate),  135.1-127.9 (Ar), 86.0, 82.9 (CMe3), 
75.4 (C-1Hex), 44.9 (CH2NH), 32.2, 31.6 (C-3Hex), 31.1 (ArCH2Ar), 
30.3 (C-2Hex), 28.3, 27.1, 30.9 (CMe3), 26.0 (C-4Hex), 22.9, 22.6 (C-
5Hex), 14.1 (C-6Hex); ESI-MS: m/z 1846.7 [M + H]+, 1868.7 [M + 
Na]+, 1885.7 [M + K]+; Anal. calcd. for C100H156N12O20: C 65.05, H 
8.52, N 9.10. Found: C 65.23, H 8.64, N 9.03.  
5,11,17,23-Tetraguanidinomethyl-25,26,27,28-tetrakis(n-
hexyloxy)calix[4]arene tetrahydrochloride (2f). To a solution of 
17 (69 mg, 0.037 mmol) in dry dioxane (7 mL), TES (59 μL, 0.37 
mmol) and 37% HCl (500 μL) were added. The mixture was stirred 
24 h at rt. Then, the solvents were evaporated under reduced 
pressure. The product was precipitated with Et2O (6 mL) and dried 
under reduced pressure. Yield: 44 mg (99%); 1H NMR (400 MHz, 
CD3OD): δ 6.75 (s, 8 H, Ar), 4.49 (d, J = 13.2 Hz, 4 H, ArCHaxAr), 
4.15 (s, 8 H, CH2NH), 3.93 (t, J = 7.2 Hz, 8 H, CH2-1Hex), 3.23 (d, J 
= 13.2 Hz, 4 H, ArCHeqAr), 2.05-1.95 (m, 8 H, CH2-2Hex), 1.55-1.31 
(m, 24 H, CH2-3Hex, CH2-4Hex , CH2-5Hex), 1.01-0.93 (m, 12 H, CH3-
6Hex); 13C NMR (100.6 MHz, CD3OD): δ 158.3 (CN), 157.6-129.0 
(Ar), 76.5 (C-1Hex), 45.9 (CH2NH), 33.6 (C-3Hex), 31.9 (ArCH2Ar), 
31.5 (C-2Hex), 27.3 (C-4Hex), 24.0 (C-5Hex), 14.5 (C-6Hex), ESI-MS: 
m/z 1045.89 [M + H]+; Anal. calcd. for C60H96Cl4N12O4: C 60.49, H 
8.12, N 14.11. Found: C 60.13, H 7.95, N 13.89. 
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